#United States #New York #Class Action #Bronstein Law #PepGen

PepGen Inc. Investors Alert: Class Action Lawsuit Filed

On June 13, 2025, Bronstein, Gewirtz & Grossman, LLC—a well-established law firm in the United States—announced the initiation of a class action lawsuit against PepGen Inc. (NASDAQ: PEPG) and several of its executives. This lawsuit specifically targets individuals and institutions who acquired PepGen securities between March 7, 2024, and March 3, 2025. The firm is urging these investors to join the class action to potentially recover damages suffered as a result of the company's alleged infractions.

Background on the Class Action

The crux of the lawsuit lies in accusations that PepGen's officers made materially false and misleading representations about the company’s business and operational prospects during the class period. Investors allege that statements concerning the efficacy and safety of PGN-EDO51, a candidate in a significant clinical study, were not only misleading but also concealed underlying issues that previously undermined these assurances. The claims suggest that the company misrepresented the full picture to benefit from inflated stock prices, eventually harming investors once the truth surfaced.

Main Allegations:

1. Effectiveness of PGN-EDO51: Defendants purportedly downplayed or misrepresented the effectiveness and safety of PGN-EDO51, leading investors to believe it was more promising than it actually was.
2. Issues with the CONNECT2 Study: The CONNECT2 study's safety and adequacy were said to be compromised, raising red flags for FDA approval, which investors were led to believe was feasible.
3. Operational Impact of the Allegations: Due to these alleged misrepresentations, PepGen is believed to be considering halting the CONNECT2 study, significantly impacting the company's future and the commercial prospects of PGN-EDO51.
4. Misleading Public Statements: The pleas for the class action revolve around the idea that the public statements by the company were materially deceptive and misleading, obscuring significant risks and challenges.

Next Steps for Affected Investors

PepGen investors who believe they have experienced losses can seek participation in this class action. The law firm emphasizes that no legal fees will be charged unless there is a successful recovery of funds. Investors are encouraged to visit the Bronstein, Gewirtz & Grossman website or contact their representatives directly to understand their rights further and review the complaint filed in court. Importantly, potential lead plaintiffs have until August 8, 2025, to make their intentions known to ensure their position in the proceedings is recognized.

Why Choose Bronstein, Gewirtz & Grossman?

With a proven track record in representing investors, Bronstein, Gewirtz & Grossman, LLC stands out for its dedication to holding companies accountable for their actions regarding securities fraud. Having successfully recovered significant amounts for clients nationwide, the law firm's expertise could be pivotal for investors looking to navigate the complexities of class action litigation.

Staying Informed

The law firm also encourages interested parties to follow them on various social media platforms for updates regarding the case and other relevant legal developments. By remaining informed, affected investors can make timely decisions to protect their interests as the class action unfolds.

In a climate where investor trust can easily be compromised, this class action may serve as an essential step towards achieving justice and accountability within the corporate sector, especially concerning investor rights. Individuals impacted by the downturn at PepGen should take prompt action to secure their place in this legal evolved.